LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

EKF Presents Cutting-Edge Point-Of-Care Diagnostic Solutions

By LabMedica International staff writers
Posted on 12 Nov 2024
Image: The new Biosen C-Line rapid benchtop glucose and lactate analyzer is on display at MEDICA 2024 (Photo courtesy of EKF Diagnostics)
Image: The new Biosen C-Line rapid benchtop glucose and lactate analyzer is on display at MEDICA 2024 (Photo courtesy of EKF Diagnostics)

EKF Diagnostics (Cardiff, Wales, UK) is attending MEDICA 2004 where the company is showcasing its diagnostic technologies and biotechnology solutions that empower healthcare and medical providers to make informed clinical decisions through point-of-care (POC) testing and life sciences applications.

EKF leads the way with cutting-edge POC diagnostic solutions that empower healthcare professionals and patients with rapid, accurate, and accessible testing capabilities and results. The company’s technologies enable informed decision-making, timely interventions, and improved patient outcomes at the POC. At this year’s MEDICA, EKF is demonstrating its POC medical devices and in-vitro diagnostic (IVD) tests for use at or near the patient’s location, engineered for fast and precise results, allowing healthcare professionals to make swift decisions. This includes EKF’s diabetes POC analyzers that measure glucose, lactate, glycated hemoglobin (HbA1C), and whole blood beta-hydroxybutyrate (BHB). These analyzers offer rapid and reliable results, giving practitioners and patients the critical information needed for clinical or lifestyle decisions within minutes. Among EKF’s diabetes point-of-care analyzers exhibited at MEDICA 2024 are Biosen C-Line, Quo-Test, STAT-Site WB, and Quo-Lab. The new Biosen C-Line, an advanced version of its industry-leading rapid benchtop glucose and lactate analyzer, has been designed to enhance usability with the latest color, touch screen, and advanced connectivity, enabling the device to seamlessly connect with hospital and laboratory IT systems, via EKF Link, to ensure patient results are quickly and securely available to clinicians.

EKF’s hemoglobin POC analyzers exhibited at MEDICA 2024 offer quick and convenient on-site blood testing, minimizing result turnaround times and enhancing patient diagnosis and outcomes. These include the DiaSpect Tm hand-held hemoglobin analyzer and Hemo Control POC hemoglobin analyzer that provides quantitative, lab-quality hemoglobin results after 25 seconds. Both devices are powered by EKF Link, which is an optional software platform that provides a flexible and secure method for connecting POC devices to hospital and laboratory IT systems. EKF Link is a middleware solution that helps healthcare providers manage their POC analyzers and associated data on one platform. A flexible and open solution that can be interfaced with most POC analyzers, allowing real-time data management, including patient test results, QC results, operator management, and analyzer configuration.

Related Links:
EKF Diagnostics

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more